THE USE OF “CATAPRES” IN THE TREATMENT OF SEVERE HYPERTENSION
- 1 October 1969
- journal article
- research article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 2 (14) , 684-687
- https://doi.org/10.5694/j.1326-5377.1969.tb107345.x
Abstract
“Catapres” is a potent drug with a unique mode of action. It is free from serious toxicity, and side effects are minor and rapidly reversible. Its major advantage is that it does not cause postural hypotension or other symptoms of sympathetic blockade. It is effective in hypertension of all grades of severity, and when not entirely effective alone, greatly potentiates the effect of guanethedine. “Catapres” is considered to be a suitable alternative to methyldopa as Initial therapy in hypertensive disease.Keywords
This publication has 9 references indexed in Scilit:
- Localization of the hypotensive effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, catapresan)European Journal of Pharmacology, 1969
- Analysis of the cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (Catapres)European Journal of Pharmacology, 1968
- Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HClEuropean Journal of Pharmacology, 1967
- The antihypertensive effects of an imidazoline compoundClinical Pharmacology & Therapeutics, 1967
- A LONG‐TERM STUDY WITH PARGYLINE IN THE TREATMENT OF HYPERTENSIONThe Medical Journal of Australia, 1967
- THE PROLONGED USE OF ALPHA METHYLDOPA IN THE TREATMENT OF HYPERTENSIONThe Medical Journal of Australia, 1964
- Guanethidine in Treatment of HypertensionBMJ, 1961